We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

FGNX:NASDAQFG Nexus Inc. Analysis

Data as of 2026-04-03 - not real-time

$4.82

Latest Price

8/10Risk

Risk Level: High

Executive Summary

FG Nexus Inc. (FGNX) is trading at $4.82, well below its 20‑day SMA of $6.39, 50‑day SMA of $8.46 and far under the 200‑day SMA of $38.51, underscoring a pronounced bearish price trend. The RSI of 24.8 places the stock in oversold territory, while the MACD line remains under its signal, reinforcing short‑term downside momentum. Volatility is extreme at nearly 90% over the past 30 days, yet beta is modest, suggesting price swings are driven more by company‑specific factors than broader market moves. Fundamentals are distressed: negative gross margin, a massive net loss per share, and negative operating cash flow, though the balance sheet shows modest debt and a low price‑to‑book ratio of 0.18 against a book value of $26.19 per share. Recent material news includes a by‑law amendment to adjust quorum thresholds and a public disclosure that the firm is selling ETH holdings as its stock slides, highlighting ongoing operational and strategic pressures. Despite these challenges, the market’s “Extreme Greed” sentiment (fear‑greed index 78.8) and a quoted upside potential of over 600% keep speculative interest alive.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Oversold RSI suggesting potential bounce
  • Bearish MACD and continuing price weakness
  • High volatility and negative cash flow

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Extremely low price‑to‑book relative to assets
  • Ongoing crypto‑related regulatory uncertainty
  • Limited operating cash flow and earnings deficits

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • Fundamental earnings erosion and negative margins
  • Sustained high volatility with modest beta
  • Strategic uncertainty after ETH liquidation and governance changes

Key Metrics & Analysis

Financial Health

Revenue Growth128.20%
Profit Margin-93.29%
P/E Ratio-2.4
ROE-7.71%
ROA-5.17%
Debt/Equity0.83
P/B Ratio0.2
Op. Cash Flow$-5717000
Free Cash Flow$-363582240
Industry P/E16.6

Technical Analysis

TrendBearish
RSI24.8
Support$4.45
Resistance$7.72
MA 20$6.39
MA 50$8.46
MA 200$38.51
MACDBearish
VolumeStable
Fear & Greed Index78.8

Valuation

Target Price$35.00
Upside/Downside626.14%
GradeUndervalued
TypeValue

Risk Assessment

Beta0.37
Volatility89.53%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.